Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →
Help us improve your experience. Please confirm your investor type:
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
IDNA ETF · iShares Genomics Immunology and Healthcare ETF
Performance & flows
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -0.86%  | -1.11% | +40.58%  | +24.39% | -38.03%  | -1.40% | +2.20% | +12.73%  | |
| Flows |
Key fund info
Essentials
Enterprise
Similar ETFs in your region
Advertisement
Risk profile
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -1.11% | +40.58% | +24.39% | -38.03% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Exposure
Sustainability
ESG Consensus® by Conser
Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about IDNA ETF's sustainability, based on their methodology.
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
IDNA’s has a Final Sustainability Grade of either B+, B, or B-.
Replication
Issuer
| AuM | ||
|---|---|---|
IVV | iShares Core S&P 500 ETF | €698.05B |
IEFA | iShares Core MSCI EAFE ETF | €159.98B |
IEMG | iShares Core MSCI Emerging Markets ETF | €137.02B |
CSSPX | iShares Core S&P 500 UCITS ETF | €127.1B |
IWDA | iShares Core MSCI World UCITS ETF | €119.79B |
Frequently asked questions about IDNA
What does iShares Genomics Immunology and Healthcare ETF, IDNA, invest in?
IDNA is a Passive ETF. This ETF provides exposure to Equities.
Which benchmark or index does IDNA replicate?
IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index NTR - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of IDNA?
IDNA carries a total expense ratio (TER) of 0.47%, indicating the annual cost for holding the fund.
When was IDNA launched?
IDNA was introduced to the market on June 11, 2019. It trades on United States
Who is the ETF issuer of IDNA?
iShares Genomics Immunology and Healthcare ETF, IDNA, is provided by iShares. Learn more about iShares here.
What is the current assets under management (AUM) of IDNA?
IDNA oversees €140M in assets as of June 11, 2026.
How has IDNA performed lately?
Based on data from June 11, 2026, IDNA returned -0.86% over the past month, -1.11% over the last three months and 12.73% year-to-date.
What are the latest inflows or outflows for IDNA?
As of June 11, 2026, IDNA recorded net flows of +€1.3M over the last month and +€13M year-to-date.
Does IDNA distribute dividends?
IDNA follows a distributing dividend policy, meaning it pays out income to investors. As of June 11, 2026, its 12-month trailing yield was 1.04%.
What are the main country or region exposures of IDNA?
As of April 30, 2026, IDNA has significant geographic allocations in USA, France and Japan.
In which sector or theme does IDNA invest in?
As of April 30, 2026, IDNA focuses largely on Health Care.
How many securities does IDNA hold and how diversified is it?
As of April 30, 2026, IDNA holds 50 positions in its portfolio, with 65.52% of assets concentrated in its top 15 holdings.
What are the main positions in IDNA?
As of April 30, 2026, IDNA top three holdings include REVOLUTION MEDICINES INC, MODERNA INC and IPSEN PROMESSES.
What is the base currency of IDNA?
The base currency of IDNA is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
